関連する実験動画
Updated: Jan 7, 2026

09:43
Measurement of Heme Synthesis Levels in Mammalian Cells
Published on: July 9, 2015
12.5K
ヘムを活性化因子および標的とするアルテミシニン:複数の薬理学的生物活性に向けて
Pan Zhu1, Xinyi Sun1, Yuting Fang1
1School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, 214122, China.
Biochemistry and biophysics reports
|January 1, 2026
まとめ
Artemisia annua由来のアルテミシニンは、新しい治療法として有望視されています。そのユニークな構造はヘムと相互作用し、抗真菌、抗がん、抗ウイルス作用の可能性を解き放ちます。
科学分野:
- 薬理学および天然物化学
- 医薬品化学
- 創薬
背景:
- アルテミシニンは、ヨモギ属から得られるユニークな過酸化物橋を持つセスキテルペン複素環式化合物です。
- その生物学的活性は、主にヘムとの相互作用を介して媒介されます。
- アルテミシニンは臨床的に証明された安全プロファイルを持っており、新しい治療用途の研究を奨励しています。
研究 の 目的:
- ヘムとの相互作用に焦点を当てたアルテミシニンの薬理学的作用をレビューすること。
- アルテミシニンの抗真菌、抗がん、抗ウイルス治療の可能性を探ること。
- 新しい医薬品および治療戦略の開発のための洞察を提供すること。
主な方法:
- アルテミシニンの作用機序に関する文献レビュー。
- アルテミシニンとヘムの相互作用を調査した研究の分析。
- アルテミシニンの多様な生物学的活性に関する現在の研究の統合。
主要な成果:
- アルテミシニンの過酸化物橋は、ヘムとの相互作用を介した生物学的活性に不可欠です。
- 証拠は、アルテミシニンが抗真菌、抗がん、抗ウイルス薬として潜在的な可能性を秘めていることを支持しています。
- ヘム中心のメカニズムは、その広範な有効性を理解するための枠組みを提供します。
結論:
- ヘムとの相互作用は、アルテミシニンの多様な薬理学的効果を理解するための鍵です。
- アルテミシニンは、様々な疾患の新しい治療法の開発に大きな可能性を秘めています。
- 医薬品開発におけるアルテミシニンベースの治療法のさらなる研究が保証されます。
関連する概念動画
Principles of Drug Action
7.8K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
7.8K
Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Drug Binding to Blood Components
472
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
472
Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
879
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
879

